Information Provided By: 
Fly News Breaks for December 5, 2016
OPHT, REGN
Dec 5, 2016 | 08:20 EDT
RBC Capital analyst Adnan Butt recommends buying Regeneron (REGN), as he believes that the stock's risk/reward ratio is positive. The analyst would be more enthused about the stock if it drops to under $350 on "a negative response to litigation" about its Praluent drug or favorable data for Ophthotech's (OPHT) Fovista, which competes with Regeneron's Eylea in the anti-VEGE market. The analyst keeps a $626 price target and an Outperform rating on Regeneron.
News For REGN;OPHT From the Last 2 Days
REGN
Apr 26, 2024 | 08:41 EDT
Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.
REGN
Apr 25, 2024 | 07:28 EDT
